IBJNews

Lilly confident of FDA approval for Amyvid, Lechleiter says

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. CEO John Lechleiter said he’s confident of gaining U.S. regulatory approval for a drug to help identify plaque in the brain associated with Alzheimer’s disease.

Outside advisers to the Food and Drug Administration voted in January against immediate approval of the medicine, Amyvid, unless the Indianapolis-based drugmaker establishes a training program and a way to ensure that results of brain scans are read consistently. Lilly aims to resolve the FDA panel’s concerns in a few months, Lechleiter said in an interview in Tokyo on Wednesday.

“We are confident that we can work with the FDA and gain approval,” said Lechleiter, 57. “This is an imaging agent that we’ve used in our own clinical studies, so we are very familiar with it.”

Amyvid’s clearance by the FDA would vindicate Lilly’s $300 million purchase of the drug’s discoverer, closely held Avid Radiopharmaceuticals, in December. The acquisition hasn’t been viewed by investors as important to Lilly’s broader focus on replacing top products before they face competition from cheaper generic versions.

Lechleiter has struggled to get new drugs on the market before patents expire in the next three years on products responsible for 65 percent of revenue.

Sales growth this year will be “in the low single digit,” Lechleiter said Wednesday. In January, the company predicted total revenue growth in 2011 would be “be flat to slightly increasing.”

Lilly rose 32 cents, or 0.9 percent, to $34.98 at the 4 p.m. close in New York Stock Exchange composite trading Tuesday. The stock has fallen 0.2 percent in the past year.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT